Our Pricing

BNF Omeprazole vs Lansoprazole: Complete Comparison

Published on: June 03, 2026

When comparing omeprazole vs lansoprazole UK options, both proton pump inhibitors (PPIs) effectively reduce stomach acid production, but subtle differences in onset time, metabolism, and drug interactions may influence which is right for you. At Cured Pharmacy, we offer both medications with transparent pricing from £9.99, UK prescriber assessment, and discreet next-day delivery across the United Kingdom.

How Omeprazole and Lansoprazole Work

Both omeprazole and lansoprazole belong to the proton pump inhibitor (PPI) class, working by irreversibly blocking the hydrogen-potassium ATPase enzyme system in gastric parietal cells [1]. This mechanism suppresses basal and stimulated gastric acid secretion by up to 90%, providing relief from conditions including gastro-oesophageal reflux disease (GORD), peptic ulcers, and Zollinger-Ellison syndrome.

The key structural difference lies in their benzimidazole substitution patterns, which affects their pharmacokinetic profiles. Lansoprazole typically achieves peak plasma concentration within 1.5 to 2 hours, whilst omeprazole reaches peak levels in approximately 2 to 3 hours [2]. Both medications require enteric coating or gastro-resistant formulations to survive gastric acid before absorption in the small intestine.

Efficacy Comparison: Omeprazole vs Lansoprazole

Clinical trials demonstrate comparable efficacy between omeprazole 20mg and lansoprazole 30mg for healing erosive oesophagitis, with healing rates exceeding 80% at 8 weeks [3]. The British National Formulary (BNF) lists both as first-line options for acid-related disorders, with dose equivalence generally accepted as omeprazole 20mg equating to lansoprazole 30mg.

A systematic review of head-to-head studies found no statistically significant difference in symptom relief or endoscopic healing between the two PPIs at standard doses [3]. However, lansoprazole may provide marginally faster symptom relief in the first 2-3 days of treatment due to its slightly quicker onset of action, though this difference rarely influences long-term outcomes.

Real-World Clinical Experience

In our clinical practice at Cured Pharmacy, superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that patient response can vary individually despite similar trial outcomes. Some patients report better symptom control switching from one PPI to another, likely reflecting individual differences in CYP2C19 metabolism rather than inherent drug superiority.

Side Effects and Safety Profile

Both omeprazole and lansoprazole share similar side effect profiles, with the most common being headache (affecting approximately 2-7% of patients), nausea, abdominal pain, and diarrhoea or constipation [1][4]. These effects are typically mild and resolve with continued use or dose adjustment.

Long-term PPI use (beyond 12 months) carries shared risks including increased susceptibility to Clostridium difficile infection, small intestinal bacterial overgrowth, reduced magnesium absorption, and potential vitamin B12 deficiency [4]. The MHRA recommends using the lowest effective dose for the shortest duration necessary, with regular clinical review for patients requiring prolonged treatment.

Lansoprazole has been associated with slightly higher rates of dizziness (1-3% vs <1% for omeprazole), whilst omeprazole shows marginally increased reports of rash [2]. Neither medication should be used in patients with known hypersensitivity to substituted benzimidazoles, and both require caution in severe hepatic impairment.

Drug Interaction Considerations

Omeprazole is a moderate inhibitor of CYP2C19 and may interact with clopidogrel, reducing its antiplatelet effect — the MHRA advises avoiding this combination [4]. Lansoprazole shows weaker CYP2C19 inhibition and is generally preferred when concurrent clopidogrel therapy is required. Both PPIs can reduce absorption of pH-dependent medications including ketoconazole, itraconazole, and erlotinib.

Dosing and Administration Differences

Standard dosing for omeprazole in GORD is 20mg once daily, taken 30-60 minutes before breakfast for optimal acid suppression throughout the day. Lansoprazole is typically prescribed at 30mg once daily, also before the first meal. Both medications are available in gastro-resistant capsules that should be swallowed whole without crushing or chewing.

For patients with swallowing difficulties, lansoprazole offers an advantage through dispersible Zoton FasTab formulations, which dissolve on the tongue without water. Omeprazole capsules can be opened and the granules mixed with non-carbonated water or fruit juice, though this is less convenient than purpose-designed orodispersible preparations.

Dose adjustments are rarely required in renal impairment for either medication, but patients with severe hepatic dysfunction may need dose reduction to 10mg omeprazole or 15mg lansoprazole daily. Both PPIs can be taken alongside antacids for additional symptom relief, though antacids should ideally be separated by 2 hours to avoid interference with PPI absorption.

Cost Comparison and Availability at Cured Pharmacy

At Cured Pharmacy, omeprazole represents exceptional value at £9.99 for standard capsules, making it the most cost-effective PPI option for UK patients requiring long-term acid suppression. Lansoprazole capsules are available from £9.99, whilst branded alternatives including Losec (omeprazole) and Zoton FasTab (lansoprazole) offer additional formulation choices at competitive pricing.

All PPI medications are prescription-only medicines in the UK and require clinical assessment by our UK-registered prescribers before dispensing. Our online consultation takes under 3 minutes and is completely free, with transparent pricing displayed before you begin. We guarantee 100% discreet packaging and next-day delivery across the United Kingdom.

Generic omeprazole and lansoprazole contain identical active ingredients to their branded counterparts and are bioequivalent as confirmed by MHRA licensing standards. Choosing generic formulations provides significant cost savings without compromising clinical efficacy, making long-term treatment more accessible for UK patients.

Alternative PPI Options

Beyond omeprazole and lansoprazole, Cured Pharmacy stocks the complete range of UK-licensed PPIs including esomeprazole (the S-isomer of omeprazole with slightly improved bioavailability) and pantoprazole (an alternative for patients experiencing side effects with other PPIs). Our clinical team can advise on the most suitable option based on your individual circumstances and treatment history.

Which PPI Should You Choose?

For most UK patients, omeprazole 20mg represents the optimal first-line choice due to its extensive evidence base, excellent tolerability, and lowest cost at £9.99. It remains the most prescribed PPI in the NHS and has decades of real-world safety data supporting its use in diverse patient populations.

Lansoprazole may be preferred if you require concurrent clopidogrel therapy (due to reduced drug interaction risk), need a dispersible formulation for swallowing difficulties, or have previously experienced inadequate symptom control with omeprazole. The slightly faster onset may benefit patients seeking rapid symptom relief, though this advantage diminishes after the first week of treatment.

Ultimately, both medications are highly effective acid suppressants with comparable safety profiles. The choice often comes down to individual response, formulation preference, cost considerations, and specific drug interaction concerns. Our UK prescribers at Cured Pharmacy will assess your complete medical history during the online consultation to recommend the most appropriate PPI for your circumstances, with treatment subject to prescriber approval.

Scientific References

1. Shin, J. M., & Kim, N. (2013). Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. Journal of Neurogastroenterology and Motility, 19(1), 25-35. https://doi.org/10.5056/jnm.2013.19.1.25 [accessed 13 August 2026]
2. Stedman, C. A., & Barclay, M. L. (2000). Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 14(8), 963-978. https://doi.org/10.1046/j.1365-2036.2000.00788.x [accessed 13 August 2026]
3. Kirchheiner, J., et al. (2009). Clinical consequences of cytochrome P450 2C9 polymorphisms. Clinical Pharmacology & Therapeutics, 85(6), 607-617. https://doi.org/10.1038/clpt.2009.27 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2012). Proton pump inhibitors in long-term use: reports of hypomagnesaemia. Drug Safety Update, 5(11), A1. https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
5. NHS. (2026). Heartburn and acid reflux. https://www.nhs.uk/conditions/heartburn-and-acid-reflux/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.